Can we Help People With the Oral Allergy Syndrome Eat Fresh Fruit?
A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients
2 other identifiers
interventional
40
1 country
1
Brief Summary
Birch pollen allergy is increasingly common. It causes asthma and early season hay fever. This is because the body recognises birch pollen and reacts to it, leading to symptoms. Many patients with birch allergy get an itchy and/or swollen mouth when they eat fresh fruit (apples, pears, peaches, plums etc). Some fruit proteins have a similar structure to birch pollen; because of this the body recognises these proteins too causing the immune system to respond. This response causes symptoms of itch and swelling inside the mouth and throat. the investigators want to find out whether it is possible to get rid of the fruit-induced symptoms by using a desensitisation procedure that has been developed for treating the kind of hay fever that is caused by birch pollen. Desensitisation involves giving a small injection of pollen just under the skin and gradually increasing the amount each week. This allows the body to build up a "tolerance" to the injected protein. When the pollen is then encountered in real life the immune system reacts less vigorously so symptoms are less severe. This treatment does reduce hay fever symptoms. Our study aims to find out if this tolerance is transferred to the fruit proteins enabling patients to eat apples with minimal symptoms. Patients will be given apple to eat in a hidden form before treatment and their response assessed. They will then receive either active or dummy pollen injections before birch pollen season. A few months after completing these injections they will have another disguised apple test to see whether their symptoms are any better. If symptoms have improved with treatment then this therapy could be offered to patients in the future. This would allow them to eat fresh fruit without worrying about unpleasant symptoms and improve their hay fever symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Jul 2012
Longer than P75 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 5, 2011
CompletedFirst Posted
Study publicly available on registry
September 12, 2011
CompletedStudy Start
First participant enrolled
July 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2016
CompletedApril 6, 2016
April 1, 2016
4.3 years
September 5, 2011
April 5, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in threshold for eating uncooked apple from baseline, compared to 1 year and 2 years following the intervention.
Baseline measurements will be taken in Winter 2012 assessing the tolerance to fresh apple in a double blind placebo controlled manner. The intervention will start in January 2013. Outcomes will be assessed using the double blind placebo controlled food challenge technique in Winter 2013 and 2014. (1 and 2 years after baseline assessment)
baseline, 1 year and 2 years
Secondary Outcomes (2)
Change in symptoms of rhinoconjunctivitis immediately after the first season of immunotherpay compared to 2 seasons of immunotherapy treatment.
baseline, 1 year and 2 years
Change in conjunctival provocation tests from baseline.
baseline, 1 year and 2 years
Study Arms (2)
Subcutaneous injection of placebo
PLACEBO COMPARATORBirch pollen immunotherapy
ACTIVE COMPARATORInterventions
Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
Eligibility Criteria
You may qualify if:
- Male or female; age 18 with no upper age limit
- History of typical fruit-related symptoms on eating apples plus or minus other plant-derived foods known to be involved in the pollen-food syndrome
- History of spring rhinitis hay fever
- Positive skin prick test to birch pollen
- Positive open food challenge to apple
You may not qualify if:
- Significant medical conditions that may affect the risks of giving BP-SIT (especially uncontrolled asthma or ongoing need for beta-blockers)
- History of moderate to severe systemic reaction to apple, defined as any of: generalised urticaria, generalised angioedema, history convincing for laryngeal oedema, collapse
- Current immunological disease (auto-immune or thyroid disease, immunodeficiency)
- Malignant disease within the past five years (Patients with previous malignant disease that is considered cured, may be included subject to the consent of their oncologist)
- Inability to attend regularly for injections and follow-up visits
- Severe atopic dermatitis
- Previous immunotherapy with birch pollen extract
- Pregnant or not using adequate contraception (post-menopausal, surgically sterilised, long-term abstinent, or barrier methods plus spermicide)
- Breast-feeding
- Evidence of current drug or alcohol misuse
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Royal Sussex County Hospital
Brighton, East Sussex, BN2 5BE, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anthony Frew, MBBS MD FRCP
Brighton and Sussex University Hospital Trust
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Research Fellow
Study Record Dates
First Submitted
September 5, 2011
First Posted
September 12, 2011
Study Start
July 1, 2012
Primary Completion
November 1, 2016
Study Completion
November 1, 2016
Last Updated
April 6, 2016
Record last verified: 2016-04